Bone and metabolic health in trans and gender diverse individuals receiving testosterone or oestrogen as cross-sex hormone therapy
| Funding period: 2018 - 2021
Related publications (2)
Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
Lachlan Angus, Shalem Leemaqz, Olivia Ooi, Pauline Cundill, Nicholas Silberstein, Peter Locke, Jeffrey D Zajac, Ada S Cheung
Background: Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfem..
Sociodemographic and Clinical Characteristics of Transgender Adults in Australia.
Ada S Cheung, Olivia Ooi, Shalem Leemaqz, Pauline Cundill, Nicholas Silberstein, Ingrid Bretherton, Emily Thrower, Peter Locke, Mathis Grossmann, Jeffrey D Zajac
Background: Over the last 10 years, increases in demand for transgender health care has occurred worldwide. There are few data on ..